ES3076129T3 - Methods of treating prostate cancer - Google Patents

Methods of treating prostate cancer

Info

Publication number
ES3076129T3
ES3076129T3 ES22713194T ES22713194T ES3076129T3 ES 3076129 T3 ES3076129 T3 ES 3076129T3 ES 22713194 T ES22713194 T ES 22713194T ES 22713194 T ES22713194 T ES 22713194T ES 3076129 T3 ES3076129 T3 ES 3076129T3
Authority
ES
Spain
Prior art keywords
methods
prostate cancer
treating prostate
treating
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22713194T
Other languages
English (en)
Inventor
Martina Malatesta
Ellen Hope Filvaroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES3076129T3 publication Critical patent/ES3076129T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES22713194T 2021-03-12 2022-03-10 Methods of treating prostate cancer Active ES3076129T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163160319P 2021-03-12 2021-03-12
PCT/US2022/019662 WO2022192481A1 (en) 2021-03-12 2022-03-10 Methods of treating prostate cancer

Publications (1)

Publication Number Publication Date
ES3076129T3 true ES3076129T3 (en) 2026-08-12

Family

ID=80952117

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22713194T Active ES3076129T3 (en) 2021-03-12 2022-03-10 Methods of treating prostate cancer

Country Status (7)

Country Link
US (1) US12016847B2 (es)
EP (1) EP4304589B1 (es)
JP (1) JP2024510975A (es)
KR (1) KR20230156107A (es)
CN (1) CN117241797A (es)
ES (1) ES3076129T3 (es)
WO (1) WO2022192481A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR073923A1 (es) 2008-10-31 2010-12-09 Medivation Technologies Inc Pirido( 4,3-b) indoles que contienen restos rigidos
CN102257076B (zh) 2008-12-18 2014-07-30 纳幕尔杜邦公司 具有新颜料的粉末涂料组合物
US8580399B2 (en) 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
KR20140068883A (ko) 2011-09-28 2014-06-09 이데미쓰 고산 가부시키가이샤 유기 전계 발광 소자용 재료 및 이를 사용한 유기 전계 발광 소자
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US9458156B2 (en) * 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EA201990240A1 (ru) * 2013-12-24 2019-06-28 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
US9580430B2 (en) * 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
RU2745999C1 (ru) * 2014-12-05 2021-04-05 Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии
US20190134004A1 (en) * 2016-06-16 2019-05-09 The University Of Chicago Methods and compositions for treating breast and prostate cancer
CN111356695B (zh) * 2017-10-27 2022-12-30 北京加科思新药研发有限公司 新的三环化合物
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent

Also Published As

Publication number Publication date
US20220296574A1 (en) 2022-09-22
KR20230156107A (ko) 2023-11-13
JP2024510975A (ja) 2024-03-12
WO2022192481A1 (en) 2022-09-15
US12016847B2 (en) 2024-06-25
EP4304589A1 (en) 2024-01-17
CN117241797A (zh) 2023-12-15
EP4304589B1 (en) 2026-06-17
EP4304589C0 (en) 2026-06-17